CJC-1295
CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH). Small controlled human studies show sustained increases in growth hormone and IGF-1. That gives the compound a real human biological signal—even though the recovery, body-composition and performance outcomes driving community interest have not been established to the same degree.
CJC-1295 stimulates your body to release more of its own growth hormone and IGF-1, which is why it has become popular for recovery, body composition and performance.
Promising downstream potential.
The strongest human evidence shows target engagement: CJC-1295 raises GH and IGF-1. Whether that reliably produces the optimization outcomes people seek is the more open question.
A long-acting signal to the GH axis.
CJC-1295 was designed to extend the action of GHRH and stimulate endogenous growth-hormone secretion for much longer than native GHRH.
The best-known human research studied a DAC form designed to bind to circulating albumin, creating a prolonged pharmacologic effect. That formulation detail matters: products sold or discussed under the broad “CJC-1295” name are not necessarily interchangeable.
The target engagement is real.
In two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults, a single CJC-1295 administration produced dose-dependent increases in mean GH of roughly 2- to 10-fold for six days or longer and mean IGF-1 of about 1.5- to 3-fold for 9–11 days. After repeated administration, mean IGF-1 remained above baseline for up to 28 days.
A separate human physiology study found that CJC-1295 increased trough and mean GH secretion and IGF-1 while preserving GH pulsatility. That is useful mechanistic evidence because it shows prolonged stimulation did not simply flatten secretion into a constant pattern.
What people are actually reporting.
Community discussions commonly focus on sleep, recovery, body composition and combinations with growth-hormone secretagogues. Reports often blur CJC-1295 with DAC and short-acting products described using similar names.
Changes in perceived sleep or recovery are self-reported and confounded by training, other compounds and formulation uncertainty. Human GH/IGF-1 responses do not establish the same benefits in muscle growth or healthy aging.
The community is interested in what comes after the lab value.
CJC-1295 has developed a strong optimization identity around recovery, sleep, body composition, training adaptation and GH-axis support.
That interest is understandable: the compound has a demonstrated human hormonal effect, and GH/IGF-1 biology intersects with several outcomes people care about. Community discussion also frequently pairs CJC-1295 with other GH secretagogues such as ipamorelin.
Where a real mechanism becomes a bigger promise.
MEANINGFUL
The biological effect is not really the mystery. CJC-1295 can meaningfully increase GH and IGF-1 in humans. The unanswered question is how reliably that hormonal change translates into the recovery, body-composition and performance benefits that drive community interest.
One name. Two very different community protocols.
CJC-1295 is a case where product identity matters. Community discussions often blur long-acting CJC-1295 with DAC and short-acting “CJC-1295 no DAC” / Mod GRF 1-29, even though their reported schedules are very different.
For products described as “no DAC” or Mod GRF 1-29, community discussions more often describe roughly 100–300 mcg per administration, commonly once or more per day. These should not be treated as interchangeable formulations.
Human studies establish that CJC-1295 with DAC can raise GH and IGF-1, but they do not establish a clinical optimization protocol. FDA has also highlighted limited clinical data and safety concerns for compounded CJC-1295. Community dosing should not be treated as an approved or medically validated regimen.
Formulation and product identity matter.
FDA's current compounding safety-risk page states that compounded drugs containing CJC-1295 may pose immunogenicity risks for certain routes and can involve peptide-impurity and active-ingredient characterization complexities. FDA also says available clinical data are limited and identifies serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.
In its 2024 review of several CJC-1295-related bulk substances for the 503A Bulks List, FDA emphasized inconsistent naming and characterization, limited clinical safety information, and lack of clinical effectiveness data for the nominated growth-hormone-deficiency use. The advisory committee voted against adding the evaluated CJC-1295 forms to the list.
Show the receipts.
| Evidence | Design | What it adds | What it cannot prove |
|---|---|---|---|
| JCEM 2006 · PMID 16352683 | Two randomized, placebo-controlled, double-blind ascending-dose trials | Demonstrated sustained, dose-dependent increases in GH and IGF-1 in healthy adults. | Does not establish muscle gain, fat loss, recovery or performance efficacy. |
| JCEM 2006 · PMID 17018654 | Human physiology study in healthy men | Found increased trough/mean GH and IGF-1 with preserved GH pulsatility. | Small mechanistic study; not an outcomes trial. |
| FDA · Current compounding safety-risk page | Regulatory safety context | Identifies immunogenicity/API-characterization concerns, limited clinical data and reported serious adverse events. | Does not negate the published pharmacodynamic effect. |
| FDA PCAC · Dec. 2024 | 503A Bulks List advisory review | Reviewed multiple CJC-1295-related bulk substances and growth-hormone-deficiency nomination. | A compounding-list review is not a clinical trial or FDA drug-approval decision. |
Read deeper.
Follow the GH-axis story.
Ipamorelin
One of CJC-1295's most common community pairings—and a useful test of complementary mechanism versus demonstrated outcomes.
Tesamorelin
Compare CJC-1295's human target-engagement story with a GH-axis peptide that has randomized outcome trials and an FDA-approved indication.
Muscle & Performance
Separate hormone changes from demonstrated improvements in strength, muscle and performance.
Community Pulse
Track where real-world experimentation is generating signals ahead of formal outcome research.
What the evidence actually shows.
Hormone biomarkers are not clinical outcomes
A small human study of long-acting CJC-1295 documented sustained elevations in growth hormone and IGF-1. That establishes a pharmacodynamic effect, not proven increases in lean muscle, improved sleep, injury recovery, or longevity. Results for long-acting CJC-1295 must not be assumed to apply to products marketed as “CJC-1295 without DAC.”
Verification source: Teichman et al. — CJC-1295 GH/IGF-1 human pharmacodynamic study.
Community Protocol Signal describes unvalidated practices and is not a clinical dosing recommendation.